Ambrosia Bio is a developer of an end-to-end enzyme-based bioprocess technology that can convert sucrose into allulose greater catalytic efficiency than current standards
Sucrose, a common sugar is associated with diabetes
R&D Focus
Sugar subsitute technology
Innovative Solution
Ambrosia Bio’s technology opens the way for the economically competitive mass production of allulose and its integration into food products as a low-calorie sucrose substitute
Solution Effectiveness
Ambrosia Bio’s rare sugars, such as Allulose, are considered ideal sugar replacements because they have a similar taste profile and sweetness to sugar but don’t have the aftertaste of many artificial sugars and low carlorific values.
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$347K
Last Funding Amount
$347K
Startup Stage
Early-Stage
Lead Investors
Gat Foods, Ginkgo Bioworks, Nesta, Space F, Brinc
People
Founders
Ziv Zwighaft
CEO
Ziv Zwighaft
Products
Demo Product or Complete Product?
Development
Awards and Recognitions
Media Apperance
GreyB
M&A and Collabs
Collab
Ambrosia Bio and Ginkgo Bioworks are partnering to use Ginkgo’s Enzyme Services to formulate an expression strain for the production of Ambrosia Bio’s proprietary enzymes
